Holen Sie sich die Stockscreener-App
0.9129
8.37%
0.0566
Schlusskurs vom Vortag:
$0.8563
Offen:
$0.869
24-Stunden-Volumen:
49,545
Relative Volume:
0.26
Marktkapitalisierung:
$28.96M
Einnahmen:
$22,000
Nettoeinkommen (Verlust:
$-61.44M
KGV:
-0.2858
EPS:
-3.1938
Netto-Cashflow:
$-43.64M
1W Leistung:
+20.24%
1M Leistung:
-3.82%
6M Leistung:
-44.43%
1J Leistung:
-68.22%
1-Tages-Spanne:
$0.8502
$0.9301
1-Wochen-Bereich:
$0.773
$0.9287
52-Wochen-Spanne:
$0.7702
$5.10
Senti Biosciences Inc Stock (SNTI) Company Profile
Firmenname
Senti Biosciences Inc
Sektor
Branche
Telefon
(650) 239-2030
Adresse
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
0.93 | 26.67M | 22,000 | -61.44M | -43.64M | -3.1938 |
VRTX
Vertex Pharmaceuticals Inc
|
433.89 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.12 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.85 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.40 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.62 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-06 | Eingeleitet | Laidlaw | Buy |
| 2022-10-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten
Growth Review: Will Senti Biosciences Inc outperform small cap indexes2026 Retail & AI Enhanced Execution Alerts - baoquankhu1.vn
Senti Biosciences, Inc. Files Form 8-K Cover Report with NASDAQ Listing Details (April 1, 2026) - Minichart
SNTI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Senti Biosciences plans holding company reorganization, stock to continue under SNTI - Investing.com India
Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026SEC Filing - TradingView
Senti Biosciences announces holding company reorganization effective by April 16, 2026SEC filing - marketscreener.com
Senti Biosciences Plans Tax-Free Holding Company Reorganization - TipRanks
Senti Biosciences, Inc. has filed documents with the U.S. Securities and Exchange Commission, officially announcing a holding company reorganization plan. - Bitget
Senti Bios to implement tax-free holding company reorganization, shares to convert and continue trading as SNTI - TradingView
Holding company reorg keeps Senti (NASDAQ: SNTI) stock structure intact - Stock Titan
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies - Bitget
Senti Biosciences publishes CAR circuit research in Cell Systems - Investing.com
Senti Biosciences publishes CAR circuit research in Cell Systems By Investing.com - Investing.com India
Senti Biosciences (SNTI) holder NEA discloses 3.78M-share, 12.1% stake - Stock Titan
Senti Biosciences (NASDAQ:SNTI) Price Target Cut to $11.00 by Analysts at Chardan Capital - Defense World
Buy Rating on SENTI-202 Driven by Strong Early AML Efficacy and De-Risking Regulatory Designations Despite Financing Overhang - TipRanks
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Senti Biosciences, Inc. (SNTI) Reports Q4 Earnings - news.alphastreet.com
Senti Biosciences stock rating held at Buy by H.C. Wainwright - Investing.com Canada
Senti Biosciences stock rating held at Buy by H.C. Wainwright By Investing.com - Investing.com India
Senti Biosciences (NASDAQ: SNTI) advances SENTI-202 gene circuit CAR-NK program - Stock Titan
Senti Biosciences 10-K: Collaboration revenue $0.022M, Net loss $61.44M, EPS $(2.73) - TradingView
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
Senti Biosciences Q4 revenue misses analyst estimates - TradingView
SNTI: Positive SENTI-202 clinical progress, RMAT status, and $61.4M net loss with $16.4M cash - TradingView
Senti Bio (NASDAQ: SNTI) posts 2025 loss as SENTI-202 gains FDA RMAT - Stock Titan
Is Senti Biosciences Inc stock good for income investorsTrade Volume Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference - Bitget
Senti Bio brings early AML cell therapy data to Innate Killer meeting - Stock Titan
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES INC (NASDAQ:SNTI) - ChartMill
Senti Biosciences Amends Lease, Restructures GeneFab Sublease - TipRanks
Senti Biosciences (NASDAQ: SNTI) halves Alameda space and resets lease with GeneFab - Stock Titan
Senti Biosciences, Inc. Enters Lease Amendment and Sublease Amendment with 1430 South Loop Owner, LLC and Genefab, LLC - marketscreener.com
Gains Report: Is Senti Biosciences Inc stock good for income investors2026 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
Macro Review: Does Senti Biosciences Inc have a sustainable dividendQuarterly Growth Report & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Should I trade or invest in Senti Biosciences Inc2026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Senti Biosciences (SNTI) Stock Analysis Report | Financials & Insights - Benzinga España
Senti Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Senti Biosciences (SNTI) officer has 10,757 shares withheld for taxes - Stock Titan
Senti Biosciences (SNTI) CEO reports 80,666-share tax withholding on RSUs - Stock Titan
Senti Biosciences Inc (SNTI) DEC/2025 Earning Prediction - Intellectia AI
Is Senti Biosciences Inc. stock a buy before product launchesWeekly Risk Report & Low Volatility Stock Recommendations - Naître et grandir
Risk Off: Is Senti Biosciences Inc stock good for income investorsJuly 2025 Levels & Growth Focused Stock Reports - baoquankhu1.vn
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference - Bitget
Miami healthcare conference talk from Senti Bio CEO will be webcast live - Stock Titan
SNTI PE Ratio & Valuation, Is SNTI Overvalued - Intellectia AI
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Senti Bio joins Cell & Gene Live cell therapy webinar - National Today
SNTI Should I Buy - Intellectia AI
Finanzdaten der Senti Biosciences Inc-Aktie (SNTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):